Zoledronic acid and related aminobisphosphonates are being used clinically in breast cancer as adjuvant chemotherapeutic agents that exhibit antitumor activity. Whether aminobisphosphonates exert antitumor effects by inhibiting protein prenylation in tumor cells or host cells remains unclear despite intensive investigation. The present study addresses this question in a novel way by developing a bioluminescence reporter for studying breast cancer cell targeting by aminobisphosphonate or other prenylation inhibitors in living animals.
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STATEMENT OF TRANSLATIONAL RELEVANCE
Zoledronic acid and related aminobisphosphonates are being used clinically in breast cancer as adjuvant chemotherapeutic agents that exhibit antitumor activity. Whether aminobisphosphonates exert antitumor effects by inhibiting protein prenylation in tumor cells or host cells remains unclear despite intensive investigation. The present study addresses this question in a novel way by developing a bioluminescence reporter for studying breast cancer cell targeting by aminobisphosphonate or other prenylation inhibitors in living animals.
Bioluminescence imaging shows that a prenyltransferase inhibitor readily targets breast cancer cells in mouse xenograft models of breast cancer. In contrast, zoledronic acid administered at a therapeutic dose fails to induce the reporter in tumors. These findings support hypotheses that aminobisphosphonates exert anti-tumor activity by targeting host rather than tumor cells. Accordingly, they focus future investigations on determining which host cell types are targeted directly by aminobisphosphonates in adjuvant chemotherapy.
Research. 
INTRODUCTION
The mevalonate biosynthetic pathway operates in all human organs and cell types to provide precursors for synthesizing steroids and isoprenoids that maintain cell membrane structure, function as endocrine hormones, produce heme A and ubiquinone for electron transport, or modify proteins post-translationally with isoprenoid lipids (prenylation) or N-linked oligosaccharide chains (1) . Mevalonate pathway inhibitors that blunt protein prenylation are being investigated intensively for treating cancer and other diseases. For example, statins, which inhibit HMG-CoA reductase to treat hypercholesterolemia, are under investigation in cancer and dementia (2) (3) (4) . Aminobisphosphonates, which inhibit farnesylpyrophosphate synthase (FPP synthase) in osteoclasts to reduce bone loss in osteoporosis and metastatic cancer (5) (6) (7) (8) , are being studied preclinically and clinically as adjuvant chemotherapeutics that exert antitumor effects in breast cancer (9) (10) (11) . Inhibitors of farnesyltransferase or geranylgeranyltransferase enzymes (FTIs and GGTIs, respectively) that attach isoprenoid lipids to proteins are being explored for treating cancer (12) (13) (14) , Hutchinson-Gilford progeria syndrome (15) , malaria (16, 17) and other diseases.
Identification of tissues and cell types targeted therapeutically by mevalonate pathway inhibitors that block protein prenylation remains a crucial but elusive goal. An important example is aminobisphosphonate-based adjuvant chemotherapy in breast cancer. Here, whether the antitumor activity of zoledronic acid or other aminobisphosphonates occurs by direct targeting of tumor cells or indirect targeting of osteoclasts or other host cell types remains unknown despite intensive investigation (6, 7, 10, 18, 19) . Such questions have persisted because surveying and quantifying drug efficacy and pharmacodynamics in tumors or various host organs, tissues and cell types in vivo has proved difficult with biochemical methods used heretofore to assess prenylation inhibition (6, 7, 20) .
Research. To eliminate this hurdle, we describe herein the development of a non-invasive, geneticallyencoded, bioluminescence-based imaging reporter that specifically and quantitatively detects direct targeting of living cells by prenylation inhibitors. We investigate the utility of this imaging reporter by introducing it into breast cancer cells and determining whether distinct classes of prenylation inhibitors can target tumor cells directly in mouse xenograft models of breast cancer.
MATERIALS AND METHODS
Reagents
MDA-MB-231 cells were obtained from Dr. Theresa Guise (Indiana University School of Medicine) (21) . Drugs were obtained from the following sources: clodronate and GGTI-298 (Sigma-Aldrich), simvastatin (Calbiochem) and zoledronic acid (Novartis Pharma AG, Basel, Switzerland).
Reporter Construction
The VP16 transcriptional activation domain from pVP16 (Clontech) was inserted downstream of the Gal4 DNA binding-domain coding region in pM3 (Clontech). The Gal4-VP16 coding region was inserted upstream of the GFP coding region in pEGFP-C1 (Clontech) to create a Gal4-VP16-GFP fusion. Oligonucleotides encoding the C-terminal 19 amino acids of Cdc42 with a functional (WT) or inactivated (CAES) prenylation site were used to generate plasmids encoding Gal4-VP16-GFP-Cdc42tail fusion proteins. The firefly luciferase (Fluc) coding region from pGL3 (Promega) was inserted into pcDNA6-V5/HisA (Invitrogen) with five copies of a consensus Gal4 DNA binding site. The Gal4x5-Fluc, ubiquitin C promoter/MCS/IRES/Renilla luciferase (from pRLTK (Promega)), the Gal4-VP16-GFP-Cdc42tail fragments, and a PGKneo cassette from pPGKneo-I (Genbank accession #AF335419) were inserted into plasmid FCIV for lentivirus packaging. HEK293T cells were co-transfected with the FCIV constructs, pVSVG, and D8.91
Research. resolved by SDS-PAGE, transferred to PVDF membranes, and probed with antibodies by standard methods. Blots were analyzed using the ChemiDoc imaging system (BioRad) and ImageLab software (BioRad) for band intensity quantification. Antibodies used were goat antiunprenylated Rap1A (Santa Cruz; C-17), anti-actin C4 (Millipore; MAB1501), HRP-conjugated rabbit anti-goat IgG (Pierce) and goat anti-mouse IgG (Pierce).
Animals and Reporter Imaging
All experiments were performed in strict accordance with the Guide for the Care and Use of 
Statistical Analyses
Results are expressed as the mean ± standard error of the mean (S.E.M.). In animal imaging studies, data were analyzed by using Student's t-test with two-tailed distribution, two-sample equal variance.
RESULTS
Imaging reporter design and characterization
We designed a bioluminescence imaging reporter ( We tested these predictions by analyzing cells expressing chimeric Gal4-VP16-GFP transactivators bearing wild type (WT) or unprenylated mutant (CAES) forms of the Cdc42 prenylation site at their C-termini (Gal4-VP16-GFP-(WT)Cdc42tail and Gal4-VP16-GFP-(CAES)Cdc42tail, respectively). In transiently transfected MDA-MB-231 breast cancer cells, the WT transactivator localized mainly to the nuclear envelope, which is contiguous with the ER membrane where enzymes responsible for Cdc42 processing reside (24) . In contrast, the mutant prenylation site transactivator localized in the nucleoplasm (Fig. 1B,C) . Similarly, treating cells with the geranylgeranyltransferase I inhibitor GGTI-298 caused the WT transactivator to accumulate in the nucleoplasm (Fig. 1B,C) . Thus, the expected consequences of genetically or pharmacologically inhibiting post-translational prenylation of the chimeric transactivator were readily observed in living cells.
We next determined whether the prenylation state of Gal4-VP16-GFP-Cdc42tail transactivators affected expression of a Gal4-driven Fluc reporter. These experiments used human MDA-MB-231 breast cancer cells stably transduced with a lentivirus that contained a Gal4 DNA binding site-driven Fluc reporter, expressed a Gal4-VP16-GFP transactivator possessing a WT or mutant (CAES) Cdc42 prenylation site at its C-terminus, and expressed Renilla luciferase (Rluc) from an IRES for concurrent normalization of Fluc reporter expression. Results indicated that basal Fluc expression was ~2-fold greater in cells expressing the mutant transactivator relative to those expressing the WT transactivator ( Fig. 2A) , indicating that the prenylated, nuclear envelope-localized WT transactivator activated the chromosomally integrated Gal4-driven Fluc reporter less effectively than the unprenylated mutant, nucleoplasm-localized transactivator.
Basal expression of the reporter driven by the WT transactivator may be due in part to the occurrence of some cells in which the fusion protein localizes to the nucleoplasm (Fig. 1B, C) . (Fig. 2A) . All compounds, including zoledronic acid, induced Fluc expression in cellulo with apparent potencies similar to those determined by measuring accumulation of unprenylated Rap1A (Fig. 2B,C; Table 1 ), an established biochemical marker of prenylation blockade (6, 7, 20) . These inhibitors failed to affect Fluc expression driven by the mutant prenlyation site transactivator, demonstrating that drug effects on reporter activity did not occur by prenylation-independent mechanisms. Moreover, clodronate (a bisphosphonate that does not inhibit FPP synthase) failed to induce Fluc expression driven by either the WT or mutant transactivator, or cause accumulation of unprenylated Rap1A (Fig. 2) . Likewise, a farnesyltransferase inhibitor (FTI-277) failed to induce the reporter or Rap1A deprenylation when used at a concentration that inhibits H-Ras farnesylation (100nM (25) ; data not shown), as expected since Cdc42 and Rap1A are geranylgeranylated rather than farnesylated. Therefore, our bioluminescence reporter displayed pharmacological sensitivity and specificity required to serve as a reliable indicator of prenylation inhibition.
Imaging prenyltransferase inhibitor action in breast cancer cells in living animals
To determine whether reporter induction by prenylation inhibitors can be imaged quantitatively in vivo, we employed breast-and bone-localized mouse xenograft models of breast cancer.
MDA-MB-231 breast cancer cells stably transduced with the reporter-bearing lentiviruses described above were implanted bilaterally in mammary fat pads or tibias of immunodeficient (nu/nu) mice. In each animal, one site received cells expressing the reporter driven by the WT transactivator, and the contralateral site received cells expressing the reporter driven by the mutant transactivator to control for potential effects of drug pharmacokinetics, tumor cell growth/survival or processes that affect reporter expression independent of prenylation. One to two weeks after tumor cell implantation, we acquired baseline bioluminescence images to establish the initial ratio of ipsilateral (WT-driven) to contralateral (CAES mutant-driven) reporter activity. We then used established regimens for administration of GGTI-298, clodronate at a obtained over time were normalized to the pre-drug ratio and expressed as fold-change over the initial value. In mice treated with the geranylgeranyltransferase inhibitor GGTI-298, Fluc expression ratios in mammary fat pad-localized tumor cells increased over time up to ~2.5-fold relative to pre-drug values (Fig. 3) . Similarly, in tibia-localized tumor cells, GGTI-298 induced Fluc reporter ratios up to ~2.3-fold relative to pre-drug controls (Fig. 4) . Importantly, vehicle (Figs. 3 and 4) and an off-target control drug (clodronate; Fig. 4 ) had undetectable effects on the reporter expression ratio, indicating that the reporter exhibited the appropriate pharmacological specificity in vivo. Therefore, the pharmacodynamics of GGTI-298 was imaged readily in tumor cells in living animals.
Assessing the direct action of zoledronic acid on breast cancer cells in living animals
Having established the utility of our system for in vivo imaging, we used it to address whether zoledronic acid, a bone matrix-associated aminobisphosphonate, can inhibit prenylation in tumor cells in vivo. Unresolved is whether zoledronic acid and related aminobisphosphonates exert antitumor activity directly within the tumor cell compartment or indirectly by targeting host tissues, a question that has been the subject of considerable investigation and debate in the breast cancer field given its importance for understanding drug mechanisms and potential for improving patient outcomes in aminobisphosphonate-based adjuvant chemotherapy (6, 18, 26, 27) .
To address this question, we employed an experimental design identical to that described above, except that instead of GGTI-298 we administered zoledronic acid at a dose equivalent to that used clinically in breast cancer patients. This dose has been shown to inhibit osteoclasts and exert antitumor activity in mouse xenograft models of breast cancer (18) . Imaging analysis indicated that reporter induction in tumor cells by zoledronic acid was undetectable in either breast-or bone-localized tumor models (Figs. 3 and 4) . However, controls indicated that zoledronic acid administration in these experiments did inhibit a known cell target (osteoclasts, as indicated by markers of bone resorption; Table 2 
supporting prior evidence indicating that this compound acts systemically (28) . In contrast, zoledronic acid administered at a therapeutically relevant dose that effectively inhibits osteoclast activity did not cause detectable induction of reporter activity in breast-localized tumor cells, as might be expected because peak circulating concentrations of this drug (1-3 μM (29) ) are ~10-fold lower than the apparent EC 50 for inducing reporter expression or inhibiting prenylation of Rap1A in cultured breast cancer cells (Fig. 2) . Crucially, however, zoledronic acid also failed to induce reporter expression even in bone-localized tumor cells, despite evidence showing that this compound and related aminobisphosphonates accumulate at high level (up to 800 μM) in osteoclast-resorbed bone (30) . Accordingly, because our imaging studies showed no indication that zoledronic acid significantly inhibits protein prenylation in breast cancer cells in living animals, these findings indicate that future work should pivot away from tumor cells and toward testing the hypothesis that zoledronic acid exerts antitumor activity indirectly by targeting host cells (6, 7, 10, 18, 19) .
Further evidence supports this concept. Depending on menopausal status, zoledronic acid administration in patients with localized breast cancer in the ABCSG and AZURE trials is associated with positive effects on disease-free survival and breast response or recurrence that are distinct from its effects on bone (11, 31, 32) . Indeed, osteoclast function apparently is dispensable for zoledronic acid to exert antitumor activity, as indicated by several studies using xenograft models of breast cancer in various mouse mutants with defective osteoclasts (6, 7, 10, 18, 19, 33) . Accordingly, identifying therapeutically relevant non-osteoclast host cell targets of zoledronic acid is likely to become a critical goal. Candidates include cells of the myeloid lineage (34) (35) (36) , which mediate tumor surveillance by the immune system, transit the bone microenvironment and are highly endocytic, potentially enabling them to access and accumulate zoledronic acid from bone at levels sufficient to inhibit FPP synthase activity and blunt protein Moreover, because FTI/GGTI combination therapy is being investigated in tumors driven by oncogenic K-Ras (14) , which can be prenylated alternatively by farnesyltransferase or geranylgeranyltransferase activity (25, 37) , reporters using a K-Ras prenylation site could be employed to detect the combined pharmacodynamic action of these two drug classes in tumors in vivo.
In conclusion, our imaging reporter removes a principal hurdle that heretofore has impeded progress toward developing prenylation inhibitors as therapeutics for treating cancer and other 
